Peer-reviewedCC BY-NC-NDACG case reports journal
IL-17 Inhibitor-Associated New Onset Inflammatory Bowel Disease: Clinical Presentation and Management: A Report of Two Cases
- 1Department of Internal Medicine, Staten Island University Hospital, Staten Island, NY
- 2Department of Gastroenterology, Cleveland Clinic Florida, FL
Related
- Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidance
- Occurrence and clinical course of immune checkpoint inhibitor-associated inflammatory arthritis and polymyalgia rheumatica-like syndromes: a systematic review and meta-analysis
- Clinical presentation and management patterns of ureteral calculi in pregnancy: a 14-year single-institution retrospective study
- Clinical Characteristics and Management of Pediatric Facial Wounds with Documented Infection or Delayed Presentation: A 25-Year Retrospective Case Series
- Response to azacitidine and the TIM-3 inhibitor, sabatolimab, in MDS and CMML is associated with distinct immune and antigen-presentation states
BibTeX
@article{vankayala2026il17,
title = {{IL-17 Inhibitor-Associated New Onset Inflammatory Bowel Disease: Clinical Presentation and Management: A Report of Two Cases}},
author = {Uday Sankar Akash Vankayala and Anas Khouri and Isabella Suarez Alcala and Adalberto Gonzalez},
journal = {ACG case reports journal},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13690439},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - IL-17 Inhibitor-Associated New Onset Inflammatory Bowel Disease: Clinical Presentation and Management: A Report of Two Cases
AU - Uday Sankar Akash Vankayala
AU - Anas Khouri
AU - Isabella Suarez Alcala
AU - Adalberto Gonzalez
PY - 2026
DA - 2026/10/01
JO - ACG case reports journal
UR - https://europepmc.org/article/PMC/PMC13690439
SN - 2326-3253
ER -